Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00676299 | A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. | PHASE1 | COMPLETED | 19 | — | — | Aug 1, 2006 | Jul 1, 2008 | Apr 26, 2010 | - | — |
| Name | Type | Description |
|---|---|---|
| JNJ-26483327 | DRUG | - |
Inclusion Criteria: * Confirmed diagnosis of solid malignancy that is advanced or refractory and progressing and for which standard treatments do not exist or are no longer effective * radiological assessment of disease within 4 weeks of first study drug administration * overall health status as de...